FLAGYL (metronidazole) by Pfizer is clinical pharmacology absorption disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. First approved in 1963.
Drug data last refreshed 14h ago
FLAGYL (metronidazole) is a small-molecule nitroimidazole antibiotic approved in 1963 for treating anaerobic bacterial and protozoal infections. It works by disrupting DNA synthesis in susceptible organisms and is used across 13+ indications including bacterial vaginosis, C. difficile infection, trichomoniasis, and intra-abdominal infections. The drug achieves therapeutic concentrations in plasma, cerebrospinal fluid, saliva, and tissue abscesses with an 8-hour elimination half-life.
As a legacy oral antibiotic approaching loss of exclusivity with no patent protections remaining, FLAGYL brand teams face significant generic competition and declining market share, resulting in smaller commercial footprints.
CLINICAL PHARMACOLOGY Absorption Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. FLAGYL 375 capsules have been shown to have a rate and extent of absorption similar to metronidazole tablets (FLAGYL) and were bioequivalent at an equal single dose of…
Worked on FLAGYL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on FLAGYL offers limited career growth in a fully genericized market; roles focus on cost optimization, market share defense, and niche positioning rather than innovation. Professionals seeking dynamic product launches or clinical advancement should evaluate emerging indications or consider transitions to higher-growth pipeline assets.